Production of therapeutic antibodies with controlled fucosylation.
about
A perspective on the structure and receptor binding properties of immunoglobulin G FcStructural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycansA prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancyFc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent CytotoxicityClearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.IgG subclasses and allotypes: from structure to effector functions.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Emerging antibody products and Nicotiana manufacturing.EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.Extracellular cyclophilin A possesses chemotaxic activity in cattle.Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.Comparison of the Fc glycosylation of fetal and maternal immunoglobulin GMulti-level glyco-engineering techniques to generate IgG with defined Fc-glycans.A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cellsGlycosylation: impact, control and improvement during therapeutic protein production.The history of monoclonal antibody development - Progress, remaining challenges and future innovationsClinical pharmacology of bispecific antibody constructs.Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Immunoglobulin Glycosylation Effects in Allergy and Immunity.Biological functions of fucose in mammals.Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.Pharmacokinetics of Monoclonal Antibodies.Inactivation of viruses using novel protein A wash buffers.Application of Lectin Array Technology for Biobetter Characterization: Its Correlation with FcγRIII Binding and ADCC.Marketing approval of mogamulizumab: a triumph for glyco-engineering.European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UKConformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses.Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.Separation of nonfucosylated antibodies with immobilized FcγRIII receptors.Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.Recombinant Proteins and Monoclonal Antibodies.Frontiers of monoclonal antibodies: Applications in medical practices.Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates.Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.
P2860
Q26827579-71A4382D-8FC0-4357-B68D-4EDA320BA549Q27675205-02CDABBD-001B-4AD8-8817-A87348FFCE81Q33411528-D5D61156-3B62-4681-9769-0327D2C43ACEQ33766365-CDB65E32-B8FE-446C-BD5B-C907CAD14FDCQ34323394-8FAE7F3E-40E7-4DBE-96C1-BDE9A8757F08Q34368678-D93106E5-7CC4-46CA-9614-16762E5C83DDQ34548319-E12B53B1-CF00-42F5-85D3-6600EB955226Q35194874-3116BD66-24A6-43CF-B312-ED00CE92A74FQ35232342-9C2D71A5-BBAB-4F67-93AE-A7641DA65054Q35262648-CAF7F25E-0CF9-458A-814C-7EBD80CF2A59Q35704154-B293650D-5999-45ED-A8E1-CC91F4FA3CCCQ35838456-2A469EF0-0702-4FA5-803E-CE3C4025A4A6Q36131665-3C29EBEC-5720-43B4-A705-AC9A55D47250Q36554708-C06ABB16-8B5B-4E16-BB1F-B6B4F7D3F772Q37461186-4C208D9D-DEAD-4573-9EB1-9B3747BACAA6Q37573768-739376BD-307B-4D9C-B753-A181C78B74ADQ38126913-1AC0037D-CA2A-4AA8-AA91-1B4395382E1AQ38311132-78D51E05-2A6C-4E25-85AB-0739B78F091BQ38364459-B204302E-F039-461C-8E02-04E1D64BB5B6Q38408253-7227908C-8E76-425E-AE74-BFD0DA9F7CACQ38591241-A3659545-7F71-4186-8704-883B45A37738Q38752663-4C4A5D35-8C8C-4DD8-B34F-2A40D985376DQ38782706-33CF5FF1-A2C8-4C4E-8A06-A8FF6ADF8C9BQ38994739-D095B400-3DE9-4609-929E-4B92AC4641D3Q39254939-196D2E76-856D-4472-9D07-FDE7A74AF5EFQ39559611-D5326F36-9A56-402F-B776-BED161C9B627Q42118646-0D9A185C-04AF-4E28-B6E6-CB129D1A28EDQ42177483-3D2FD941-68AE-4580-A2E2-4C17A9564800Q42293231-7A265DF2-1B10-40E8-876F-3CEE160DB88FQ42333453-E6AD22A8-2D48-4DB8-8D27-F7787EA32ED5Q42580265-4A571A08-F80D-47EB-AEC9-70EDDECD6A5FQ42645388-32DD5E93-D0E8-48FB-BCD5-3167CEB0DBC2Q43246232-75926714-4F0A-4FFA-8B9F-9E670D27CBF4Q44852748-7A8A9916-A47E-44E9-8601-548364F6A846Q46360891-2BC2372E-A572-4705-9982-972C3AC5A22BQ47190029-35733B80-275F-4512-9A3A-1A2B37269645Q47602370-469A6723-3861-4FF5-AC91-6B7DF44DCDB0Q47603614-9091DE85-10CB-4FA5-891C-7FC91B6F80EAQ47874093-D81E3068-7E6F-4F3D-B45A-584CFE89EBBBQ48278134-257FA229-EEE6-441D-81B6-21CAF393DADC
P2860
Production of therapeutic antibodies with controlled fucosylation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Production of therapeutic antibodies with controlled fucosylation.
@en
Production of therapeutic antibodies with controlled fucosylation.
@nl
type
label
Production of therapeutic antibodies with controlled fucosylation.
@en
Production of therapeutic antibodies with controlled fucosylation.
@nl
prefLabel
Production of therapeutic antibodies with controlled fucosylation.
@en
Production of therapeutic antibodies with controlled fucosylation.
@nl
P2860
P356
P1476
Production of therapeutic antibodies with controlled fucosylation.
@en
P2093
Mitsuo Satoh
Naoko Yamane-Ohnuki
P2860
P304
P356
10.4161/MABS.1.3.8328
P577
2009-05-28T00:00:00Z